A randomized, open-label phase II studyevaluating the efficacy and safety of FOLFOX-4plus cetuximab versus UFOX plus cetuximab asfirst-line therapy in subjects with metastaticcolorectal cancer

ABSTRACT: Primary objectives: The primary objective of this study is to compare the PFS in subjects receiving cetuximab plus either UFOX or FOLFOX-4 as initial treatment for metastatic colorectal cancer. Primary endpoints: The primary variable is progression-free survival.

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2519204 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR